JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oie, S.
Right arrow Articles by Chiang, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oie, S.
Right arrow Articles by Chiang, J.

Decreased elimination of unbound prazosin in the presence of alpha 1- acid glycoprotein in the rat in vivo

S Oie, F Fiori and J Chiang

The kinetics of unbound prazosin under constant i.v. infusion (800 ng/kg/min) and after i.v. bolus (160 micrograms/kg) were determined in control rats and in rats pretreated with human alpha 1-acid glycoprotein (AAG). Administration of 40 and 100 mg/kg of AAG decreased the unbound fraction in plasma of prazosin from 0.238 to 0.175 and 0.090, respectively. Administration of 40 mg/kg of AAG decreased the clearance of prazosin with respect to unbound drug (CLu) on the average by 40%. There was no statistically significant difference in the decrease of CLu between animals given constant infusions and i.v. bolus of prazosin. Increasing the administered dose of AAG from 40 to 100 mg/kg caused no further decrease in CLu. Because prazosin is a low-to- medium extraction ratio compound in the rat, this decrease in CLu indicates that AAG has an inhibitory effect on the elimination of prazosin that goes beyond a simple protein binding effect. The apparent volume of distribution of unbound drug, steady state, VUss, decreased from 12.4 to 7.7 liters/kg, and the red blood cell/plasma water concentration ratio decreased from 9.2 to 4.0 after administration of AAG. The possible mechanisms for the observed effects are discussed.

Volume 241, Issue 3, pp. 934-938, 06/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1987 by the American Society for Pharmacology and Experimental Therapeutics.